



Polartechnics Ltd

MEDIA RELEASE

Polartechnics Limited announces findings regarding revolutionary new cervical cancer screening device

A study involving 651 women has confirmed that a new cervical cancer screening product, TruScreen, offers increased detection of serious pre-cancerous abnormalities of the cervix. The results of the TruScreen trials were delivered today to Gynaecologists and women's health specialists attending the Australian Colposcopy and Cervical Pathology (ASCCP) conference in Rotorua in New Zealand.

Dr Chris Dalrymple*, who presented the results of this important clinical trial, said that the trial results showed that TruScreen, when used together with the Pap test increases the accuracy of detection by 33%. This means that by using both tests more pre-cancerous changes on the cervix are accurately identified. In the trials the sensitivity, a measure of test accuracy, of the combined test was 93% compared to only 70% for Pap test alone.

Dr Dalrymple said: "TruScreen provides a totally new approach. We have had the Pap test now for over 50 years -with its well documented limitations. These trial results show that TruScreen, combined with the Pap test, reveal more abnormalities than the Pap alone. TruScreen is also very reassuring because the patient receives her results on the spot."

Dr Dalrymple went on to say: "If the result is positive, the patient can be immediately referred for a biopsy. TruScreen represents an important change in mass screening for cervical cancer."

These significant findings will be published in the International Journal of Gynaecological Cancer, a major scientific peer reviewed publication.

Other Australian gynaecologists who have been using TruScreen in their practices will also report their experiences with TruScreen technology at the conference.

Dr David Itzkowic, who runs a practice in Sydney's Eastern Suburbs said: "I'm very pleased to have TruScreen in my practice. It's an extremely valuable tool. In the past 3 months I have used TruScreen on 135 patients. It has identified 3 cases of confirmed

pre-cancerous disease that were missed by the Pap test. After 50 years of having only the Pap test it is great to be able to offer women an option with greater reliability, no discomfort and improved service”.

Dr Michael Quilter of Wollongong also found that TruScreen identified cases missed on the Pap test. He reported that: “In gynaecological practice TruScreen may have an important role as women who have had abnormal changes in the past are likely to be anxious. For them there is great benefit and relief in having an immediate result.”

After a long period of development, TruScreen will become available in Australian and New Zealand on a more widespread basis. It is also being sold in Italy.

For further information please contact Margot McKay on 0412132769

* Dr Dalrymple is Senior Gynaecological Oncologist at Royal Prince Alfred Hospital, Sydney, is on the Executive of the Australian Colposcopy and Cervical Pathology (ASCCP) and is Chairman of the Australian Society of Gynaecological Oncology (ASGO)